Cellectis To Present Pre-Clinical Data On TALEN-Edited Smart CAR T-Cells Supporting Improved Solid Tumor Targeting At The Society For Immunotherapy Of Cancer's 37th Annual Meeting November 10
Cellectis To Present Pre-Clinical Data On TALEN-Edited Smart CAR T-Cells Supporting Improved Solid Tumor Targeting At The Society For Immunotherapy Of Cancer's 37th Annual Meeting November 10
Cellectis will present a poster on TALEN-edited smart CAR T-cells targeting MUC1- expressing solid tumors. MUC1 is a tumor-associated antigen that is overexpressed in triple-negative breast cancer (TNBC) and other solid tumor malignancies.NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on TALEN-edited smart CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022), to be held in Boston, M.A. and virtually on November 8-12, 2022.
紐約，2022年10月5日(環球網)--Cellectis(公司)(納斯達克：CLLS)，一家臨牀階段的生物技術公司，利用其開創性的基因編輯平臺開發拯救生命的細胞和基因療法，今天宣佈關於TALEN的臨牀前數據-編輯的智能汽車T細胞，以克服針對實體腫瘤的關鍵挑戰，將在將於2022年11月8日至12日在馬薩諸塞州波士頓舉行的第37屆癌症免疫治療年會(SITC 2022)上發表。
Presentations include:
演示文稿包括：
Poster presentation:
海報演示文稿：
Cellectis will present a poster on TALEN-edited smart CAR T-cells targeting MUC1- expressing solid tumors. MUC1 is a tumor-associated antigen that is overexpressed in triple-negative breast cancer (TNBC) and other solid tumor malignancies.
Cellectis將在TALEN編輯的智能汽車T細胞上展示一張海報，目標是表達MUC1的實體腫瘤。MUC1是一種腫瘤相關抗原，在三陰性乳腺癌(TNBC)和其他實體腫瘤中過度表達。
Title: Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth
Poster Number: 217
Presenter: Piril, Erler Ph.D., Scientist II, Immuno-Oncology, Cellectis
Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C
標題：多裝甲同種異體MUC-1 CAR T細胞有效控制三重負乳腺癌生長
海報編號: 217
主講人：皮裏爾，Erler博士，二級科學家，免疫腫瘤學，盲腸炎
日期/時間：11月10日星期四，C廳上午9：00至晚上9：00張貼海報
Poster presentation:
海報演示文稿：
Cellectis will present a poster on innovative T-cell engineering strategies designed to increase the activity of CAR T-cells for solid tumors while mitigating toxicity risk.
Cellectis將展示一張關於創新T細胞工程戰略的海報，該戰略旨在提高CAR T細胞對實體腫瘤的活性，同時降低毒性風險。
Title: TALEN-edited smart CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy
Poster Number: 325
Presenter: Shipra Das Ph.D., Senior Scientist & Team Leader Immuno-Oncology, Cellectis
Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C
標題：塔倫-編輯的智能汽車T細胞利用固體腫瘤微環境進行特異有效的免疫治療
海報編號: 325
主講人：Shipra Das博士，Cellectis高級科學家兼免疫腫瘤學團隊負責人
日期/時間：11月10日星期四，C廳上午9：00至晚上9：00張貼海報
Full text of the abstracts will be released on the SITC website at 8:00 a.m. EST on November 7, 2022.
摘要全文將於上午8點在SITC網站上發佈。美國東部時間2022年11月7日。
